Educational Blogs


Medication Interactions and Pain: Why Review Comes First
Pain


Medication Interactions and Pain: Why Review Comes First

When patients seek clinical evaluation for pain, they often focus on where the pain is located or how severe it feels. Clinicians begin somewhere else: with a careful review of medications. This st...

Read more
Why Pain Requires Individualized Clinical Assessment
Pain

Why Pain Requires Individualized Clinical Assessment

Pain is one of the most personal health experiences a person can have. Two individuals may describe similar symptoms yet experience pain in very different ways, over different timelines, and with d...

Read more
How Clinicians Evaluate Chronic Pain Through Telehealth
Pain

How Clinicians Evaluate Chronic Pain Through Telehealth

Chronic pain is one of the most common reasons people seek clinical care, yet it is also one of the most complex concerns to evaluate. Unlike acute pain tied to a clear injury or illness, chronic p...

Read more
Rethinking Pain Management: The Role of Clinician-Guided Cannabinoid Care
Pain

Rethinking Pain Management: The Role of Clinician-Guided Cannabinoid Care

Chronic pain affects millions of people and is one of the most common reasons individuals seek alternative or integrative treatment options. From joint pain and nerve discomfort to inflammatory con...

Read more
Important safety information

Prescription cannabinoid therapies require clinical oversight.

Common side effects

Prescription cannabinoid therapies may cause drowsiness, fatigue, changes in appetite, diarrhea, and dry mouth. Effects vary by patient, dose, and formulation.

Drug‑interaction risk

CBD can affect how the body metabolizes other medications through cytochrome P450 liver enzymes, which may alter the effectiveness or safety of prescriptions including blood thinners, anti‑seizure medications, and some antidepressants. Disclose all current medications and supplements to your clinician during evaluation.

Liver‑enzyme monitoring

Elevated liver enzymes have been observed in clinical research on CBD, particularly at higher doses. Your clinician may recommend liver‑function testing before or during your protocol. Patients with existing liver conditions require additional review.

Not FDA‑approved

Compounded cannabinoid formulations are prepared under FDA 503A regulations for individual patients. They are not FDA‑approved drugs and have not been evaluated by the FDA for safety, efficacy, or quality in the same way as commercial pharmaceuticals. Compounded medications are prescribed when a clinician determines a commercially available product is not appropriate for a specific patient.

This information is provided for educational purposes and does not replace clinical advice. Speak with a licensed clinician before beginning any cannabinoid protocol. Telehealth currently available in Colorado only. Individual results vary. Prescription decisions are made solely by a licensed clinician and are never automatic.